Clinical Trial Update: Lokelma for RAAS Maximisation in CKD & Heart Failure. [Phase 3]

View source ↗

Summary

Phase 3 trial update for Lokelma evaluating potassium management to maximize RAAS inhibition in chronic kidney disease and heart failure with reduced ejection f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Sponsor: St George's, University of London | Conditions: Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: COMPLETED